Even though initially developed as anti-cancer agents, class I and II HDAC inhibitors have shown therapeutic utility in the treatment of chronic immune and inflammatory disorders such as rheumatoid arthritis [11], colitis [12], airway inflammation and asthma [13]. Here, HDAC9 is linked to colitis.